Both drug classes have strong cardiovascular outcome trial data. Both are prescribed in longevity medicine. Here is how the evidence for each compares across mechanism, outcomes, and patient profile.
SGLT2 inhibitors and GLP-1 receptor agonists are the two drug classes with the strongest cardiovascular outcome trial evidence in contemporary longevity medicine. Both are rated Strong in the Geroevidence tier system. Their evidence profiles differ in important ways.
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) work primarily through glycosuria and osmotic diuresis, with secondary effects on ketone production, renal tubular protection, and cardiac preload reduction. GLP-1 agonists (semaglutide, liraglutide, tirzepatide) work through incretin signaling — slowing gastric emptying, enhancing insulin secretion, reducing appetite, and producing anti-inflammatory effects through central and peripheral pathways.
SGLT2 inhibitor evidence: EMPA-REG OUTCOME (CV death HR 0.62, all-cause mortality HR 0.68 in T2D + CVD), DECLARE-TIMI 58 (HF reduction in broader population), DAPA-HF (HF benefit in non-diabetics), CREDENCE (renal protection), EMPEROR-Reduced (HF in non-diabetics). Strongest signal: heart failure prevention and renal protection, both considered class effects. GLP-1 agonist evidence: LEADER (CV death HR 0.78 in T2D + CVD), SUSTAIN-6 (MACE reduction), SELECT (MACE reduction in non-diabetic obese adults — the critical population for longevity medicine off-label use). Strongest signal: MACE reduction, CV mortality reduction in T2D populations; SELECT extends this to non-diabetic obese adults.
For longevity medicine patients without diabetes or established CVD, the SELECT trial evidence is most directly applicable for GLP-1 agonists (obese adults with CVD). For SGLT2 inhibitors, primary prevention evidence is less direct — most outcome trials enrolled patients with established CVD or high risk. However, SGLT2 inhibitors have the advantage of renal protective effects that are relevant across aging populations regardless of CVD status. Heart failure prevention is also highly relevant to aging — HF is among the most common causes of disability and mortality in older adults.
Both drug classes have Strong evidence tiers based on cardiovascular outcome trial data. GLP-1 agonists have the SELECT trial advantage — direct evidence in non-diabetic obese adults with established CVD. SGLT2 inhibitors have broader renal protection data and a more established heart failure prevention benefit. For a longevity medicine patient with obesity and CVD but no diabetes, SELECT-eligible criteria suggest GLP-1 agonists. For a patient with CKD, heart failure risk, or metabolic syndrome without obesity, SGLT2 inhibitors may have the edge. Many longevity physicians consider both classes complementary in appropriate patients.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.